Navigation Links
Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
Date:2/22/2010

EMERYVILLE, Calif., Feb. 22 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, reported today on the publication of results from a preclinical study that demonstrated the synergistic effects of triple combination antiviral drug (TCAD) therapy against multiple strains of seasonal, pandemic, and avian influenza A (H1N1, H3N2 and H5N1) virus, including three strains of amantadine resistant pandemic H1N1 and two strains of oseltamivir resistant seasonal H1N1.

The results of this study have been published in PLoS One under the title: Triple Combination of Amantadine, Ribavirin, and Oseltamivir is Highly Active and Synergistic Against Drug Resistant Influenza Virus Strains In Vitro. PLoS One is an interactive open-access journal for the communication of all peer-reviewed scientific and medical research published by the Public Library of Science (PLoS). Interested parties may view the article on the PLoS website under Presentations and Publications.

The data demonstrated that amantadine, ribavirin and oseltamivir, when administered as components of a triple combination therapy, had a synergistic effect (i.e. enhanced antiviral activity) against multiple amantadine- and oseltamivir-resistant virus strains.  The data also demonstrated that the antiviral activity of the TCAD regimen is greater than the antiviral activity of any double combination.  Further, when investigating amantadine-resistant virus strains against which amantadine had no significant antiviral activity as a single agent, the addition of amantadine at clinically relevant concentrations to the combination of ribavirin and oseltamivir resulted in a dose dependent inhibition of virus replication. This was similarly observed for oseltamivir in strains that were oseltamivir resistant.  These data demonstrate that the TCAD therapy may have broad-spectrum activity against the circulating resistant influenza A strains, including novel influenza A/H1N1, the pandemic influenza strain.

"Given the fact that the majority of influenza A viruses are resistant to at least one antiviral, these data suggest the advantage of a triple combination drug therapy approach over double combinations or monotherapy," said Gregory Went, Ph.D., chief executive officer and chairman of Adamas.  "We are encouraged about the potency of TCAD therapy measured in preclinical studies and look forward to continued validation of TCAD therapy with our academic and clinical partners."

About TCAD

Adamas is pioneering triple combination antiviral drug (TCAD) therapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway.  TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu ® (oseltamivir phosphate, Roche).  Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies.  In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. TCAD therapy for influenza A is currently being investigated in a Phase 2 human clinical study.

About Adamas

Adamas is an emerging pharmaceutical company focused on developing small molecule Advantaged Therapeutics to treat neurological and infectious diseases, including influenza A, the cause of the current flu pandemic.  Adamas' approach to pharmaceutical development is to identify synergistic drug mechanisms that can be developed as optimized combination drug therapies to increase safety, efficacy and compliance, thus improving upon the standard of care. Adamas is headquartered in Emeryville, California, with operations in Bangalore, India.  For more information about Adamas, please visit www.adamaspharma.com.  

SOURCE Adamas Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.adamaspharma.com

'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
2. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
3. Ritter Pharmaceuticals Joins NIH Conference Discussions on Lactose Intolerance and Associated Health Risks
4. Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
5. Alexza Pharmaceuticals Promotes Mark K. Oki to Vice President, Finance and Controller
6. Jazz Pharmaceuticals Announces FDA Acceptance of its New Drug Application for JZP-6 (sodium oxybate) for the Treatment of Fibromyalgia
7. Transdel Pharmaceuticals Announces Management Reorganization
8. Merz Pharmaceuticals Introduces New Mederma(R) Stretch Marks Therapy Now Available in Drugstores Nationwide
9. GlaxoSmithKline President of North America Pharmaceuticals, Deirdre Connelly, Named 2010 Woman of the Year by the Healthcare Businesswomens Association
10. Oramed Pharmaceuticals Expands Scientific Advisory Board With the Appointment of John Amatruda, M.D.
11. Alexza Pharmaceuticals to Host 2010 Investor/Analyst Day on Thursday, February 18, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... Halo Labs announces the launch of a novel low ... Horizon at PEGS 2017 in Boston ... visible particulate matter in biopharmaceutical samples to enable for ... candidate selection and pre-formulation. Halo Labs is ... Elion Labs for system validation. "We are very ...
(Date:4/20/2017)... Mass. , April 20, 2017  RXi ... developing innovative therapeutics that address significant unmet medical ... data from the Company,s consumer product development program, ... at the Society for Investigative Dermatology (SID) 76 ... to advance and promote the sciences relevant to ...
(Date:4/20/2017)... , April 20, 2017 Research ... Pharmacogenomics Market Size, Market Share, Application Analysis, Regional Outlook, Growth ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 ... Mn by 2024, expanding at a CAGR of 5.6% from ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... expanded distribution of the GlycoMark test throughout the Northeast U.S. , GlycoMark ... patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week ...
(Date:4/28/2017)... ... , ... The Radiology Business Management Association (RBMA) is pleased to ... election process has been in place since the RBMA was founded in 1968 with ... succeeds Jim Hamilton, MHA, CMM, FRBMA, as president. Dr. Dickerson the chief executive officer ...
(Date:4/28/2017)... ... 28, 2017 , ... The Texas Cord Blood Bank (TCBB), a program of ... team at Women’s Hospital at Renaissance in Edinburg for their outstanding efforts in collecting ... decide to donate. , “Women’s Hospital at Renaissance has been a collection partner ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... People are ... older people. “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa ... Hearing Associates of Greater Boston, in a NALA North American Speaker Series ...
(Date:4/28/2017)... ... April 28, 2017 , ... Researchers at ... ActiGraph’s CentrePoint Data Hub in a sample of participants enrolled in ... activity and sleep monitoring solutions for the global scientific community. The company’s new ...
Breaking Medicine News(10 mins):